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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
Lactobacillus johnsonii NCC 533 (La1) (CNCM I-1225) and improving 
immune defence against pathogenic gastro-intestinal microorganisms 
(ID 896), and protection of the skin from UV-induced damage (ID 900) 
pursuant to Article 13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to Lactobacillus johnsonii NCC 533 (La1) (CNCM I-1225) and improving immune defence 
against pathogenic gastro-intestinal microorganisms, and protection of the skin from UV-induced 
damage. The scientific substantiation is based on the information provided by the Member States in 
the consolidated list of Article 13 health claims and references that EFSA has received from Member 
States or directly from stakeholders. 
The food constituent that is the subject of the health claim is Lactobacillus johnsonii NCC 533 (La1) 
(CNCM I-1225). The Panel considers that Lactobacillus johnsonii NCC 533 (La1) (CNCM I-1225) is 
sufficiently characterised.  
Improving immune defence against pathogenic gastro-intestinal microorganisms  
The claimed effect is “natural defence/immune system”. The target population is assumed to be the 
general population. In the context of the clarifications from Member States and the references 
provided, the Panel assumes that the claimed effect refers to improving immune defence against 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-1683, EFSA-Q-2008-1687, adopted on 
25 March 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
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Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group 
on Gut/Immune: Jean-Louis Bresson, Maria Carmen Collado, Miguel Gueimonde, Daisy Jonkers, Martinus Løvik, Bevan 
Moseley, Maria Saarela, Seppo Salminen, Yolanda Sanz, Stephan Strobel, Daniel Tomé and Hendrik van Loveren. 
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pathogenic gastro-intestinal microorganisms. The Panel considers that improving immune defence 
against pathogenic gastro-intestinal microorganisms is a beneficial physiological effect. 
No human studies from which conclusions could be drawn for the scientific substantiation of the 
claim were provided. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of Lactobacillus johnsonii NCC 533 (La1) (CNCM 
I-1225) and improving immune defence against pathogenic gastro-intestinal pathogens. 
Protection of the skin from UV-induced damage (ID 900) 
The claimed effect is “skin health”. The target population is assumed to be the general population. In 
the context of the clarifications provided by Member States, the Panel assumes that the claimed effect 
refers to protection of the skin from UV-induced damage. The Panel considers that protection of the 
skin from UV-induced damage is a beneficial physiological effect. 
No human studies from which conclusions could be drawn for the scientific substantiation of the 
claim were provided.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of Lactobacillus johnsonii NCC 533 (La1) (CNCM 
I-1225) and protection of the skin from UV-induced damage. 
KEY WORDS 
Lactobacillus johnsonii NCC 533 (La1) (CNCM I-1225), immune, gastro-intestinal pathogens, skin, UV 
exposure, health claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the information originally provided. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claims is “Lactobacillus johnsonii NCC 533 
(La1) (CNCM I-1225)”, (hereafter L. johnsonii NCC 533 or L. johnsonii La1).  
The identification/characterisation of the strain L. johnsonii NCC 533 has not been included in the 
studies provided but different studies on phenotypic and genotypic identification/characterisation can 
be found in the literature (Berger et al., 2007; Ventura et al., 2004). In addition, the genome sequence 
of L. johnsonii NCC 533 is publicly available at the NCBI database (accession NC_005362) 
(Pridmore et al., 2004). A culture collection number from the Collection Nationale de Cultures de 
Microorganismes (CNCM) was also provided. The strain Lactobacillus acidophilus La1 has been 
re-classified as L. johnsonii La1. 
The Panel considers that the food constituent, Lactobacillus johnsonii NCC 533 (La1) 
(CNCM I-1225), which is the subject of the health claims, is sufficiently characterised. 
2. Relevance of the claimed effect to human health 
2.1. Improving immune defence against pathogenic gastro-intestinal microorganisms (ID 
896) 
The claimed effect is “natural defence/immune system”. The Panel assumes that the target population 
is the general population.  
In the context of the clarifications from Member States and the references provided, the Panel 
assumes that the claimed effect refers to improving immune defence against pathogenic 
gastro-intestinal microorganisms.  
The Panel considers that improving immune defence against pathogenic gastro-intestinal 
microorganisms is a beneficial physiological effect. 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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2.2. Protection of the skin from UV-induced damage (ID 900) 
The claimed effect is “skin health”. The Panel assumes that the target population is the general 
population. 
In the context of the clarifications provided by Member States, the Panel assumes that the claimed 
effect refers to protection of the skin from UV-induced damage.  
The Panel considers that protection of the skin from UV-induced damage is a beneficial physiological 
effect. 
3. Scientific substantiation of the claimed effect 
3.1. Improving immune defence against pathogenic gastro-intestinal microorganisms 
(ID 896) 
Among the references provided in relation to the claim, six citations were incomplete and the 
corresponding references could not be retrieved, the full texts of four references were not accessible 
to the Panel after every reasonable effort was made to retrieve them, three review papers did not 
provide original data, one reference was in Japanese and no translation into an EU language was 
available to the Panel, one human study did not address outcomes related to the claimed effect, three 
human studies addressed the effects of different combinations of food constituents and did not allow 
conclusions to be drawn on the effects of L. johnsonii La1 alone (e.g. L. johnsonii La1 plus 
S. thermophilus without controlling for the effect of S. thermophilus alone), and one human study 
used an administration route (i.e. via naso-gastric tube) which is not relevant for the substantiation of 
a claim on a food for oral consumption. The Panel considers that no conclusions can be drawn from 
these references for the scientific substantiation of the claim.  
The remaining references included six human studies, 11 animal studies and 26 in vitro studies. 
In a randomised, double-blind, placebo-controlled cross-over study (Yamano et al., 2006), 22 young 
healthy Japanese women (aged 20-22 years) received either 120 mL of fermented milk with 
L. johnsonii La1 (NCC 533) (1x10
9
 CFU/day) and Streptococcus thermophilus (1x10
8
 CFU/day) or 
the same amount of fermented (placebo) milk with S. thermophilus (1x10
8
 CFU/day) only, for 21 days 
each with a wash-out period of 29 days in between. The effect of L. johnsonii La1 (NCC 533) on the 
intestinal microbiota (15 microorganisms or groups thereof) was investigated, including the 
appearance rate and numbers of lecithinase-positive Clostridium in the faeces. The Panel notes that 
the high number of primary outcomes tested was not taken into account in the statistical analysis, and 
that the number of lecithinase-positive Clostridium carriers was low. Therefore, it cannot be excluded 
that the borderline statistical significance of the difference in the number of lecithinase-positive 
Clostridium reported between the intervention and placebo groups is a chance finding. The Panel 
considers that no conclusions can be drawn from this study for the scientific substantiation of the 
claim.  
Brunser (2000) reported on a partially randomised and blinded study on anti-polio secretory IgA in 
saliva after oral polio vaccination in groups of infants (116 were enrolled) between four and six 
months old, in which the primary outcome was the safety of the formula and the secondary outcomes 
included the immune response to oral polio vaccination (IgA in saliva) and faecal bacterial 
composition. In another study, Brunser et al. (2006) evaluated the effect of L. johnsonii La1 on faecal 
bacterial counts in 90 infants (around 3.5 months of age). The Panel notes that the immune system in 
early childhood is still developing, and that the microbiota is different in composition, diversity, 
stability and evolution from that of adults. The Panel considers that the evidence provided does not 
establish that data from these study populations can be extrapolated to the general population. 
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In a double-blind, placebo-controlled study by Donnet-Hughes et al. (1999), a total of 42 volunteers 
were randomised to receive S. thermophilus only, S. thermophilus with 10
9
 CFU L. johnsonii La1, or 
S. thermophilus with 10
8
 CFU L. johnsonii La1 daily for three weeks after a 3-week run-in phase in 
which all volunteers received milk. Outcome measures included phagocytic activity and leukocyte 
oxidative burst. Two other human intervention studies with a parallel-group design (Schiffrin et al., 
1995; 1997) in which individuals were given fermented milk with L. acidophilus La1 (re-classified as 
L. johnsonii La1) (7x10
10
 CFU/day) or Bifidobacterium bifidum strain Bb-12 (currently B. animalis, 
1x10
10
 CFU/day) for three weeks were provided. Outcome measures were lymphocyte subsets and 
leukocyte phagocytic activity. In these studies, only within-group (and not between-group) 
comparisons were reported for the outcome measures. The Panel considers that no conclusions can be 
drawn from these studies for the scientific substantiation of the claim.  
Eleven animal studies on the effects of L. johnsonii La1 on the development and function of the 
immune system in gnotobiotic mice, as well as on oral tolerance, antibody production, and other 
parameters of immune function in mice were cited. None of the studies addressed outcomes directly 
related to pathogens. The in vitro studies dealt with the proliferative and cytokine responses of 
various immune and epithelial cell types, cellular interactions, bacterial adhesion to epithelial cells 
and production of bacteriocins. The Panel considers that evidence provided in animal and in vitro 
studies is not sufficient to predict the occurrence of an effect of L. johnsonii La1 consumption on 
improving immune defence against pathogens in humans. 
The Panel notes that no human studies from which conclusions could be drawn for the scientific 
substantiation of the claim were provided.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of Lactobacillus johnsonii NCC 533 (La1) (CNCM I-1225) and improving immune 
defence against pathogenic gastro-intestinal microorganisms. 
3.2. Protection of the skin from UV-induced damage (ID 900)  
Among the references provided in relation to the claim were unpublished reports, meeting abstracts or 
posters, which were either not accessible to the Panel or did not contain sufficient information for a 
full scientific evaluation. One animal study on the development of atopic dermatitis did not address 
outcomes related to the claimed effect. The Panel considers that no conclusions can be drawn from 
these references for the scientific substantiation of the claim.  
In a double-blind, randomised, placebo-controlled human intervention study (Peguet-Navarro et al., 
2008), 54 healthy male volunteers (aged 20 to 40 years) received daily oral supplementation with 
either L. johnsonii La1 (1x10
10
 CFU, n=27) or placebo (maltodextrin, n=27) for 66 days. Suction 
blister roofs and skin biopsies were taken from the right and left buttocks of each volunteer at 
baseline, and the UV minimal erythemal dose (MED) was determined. On day 56, the volunteers were 
exposed to 1.5 MED twice within 10 hrs on a 10x10 cm area on the right buttock from a 1,000 W 
xenon solar simulator, with an exposure spectrum according to the standards for determining sun 
protection factors. On days 1, 4 and 10 post-irradiation, suction blister roofs and biopsies were again 
collected from the right and left buttocks. Results were based on comparisons between exposed and 
un-exposed areas for each subject, and included immuno-histochemical analysis (scoring) of a number 
of cellular markers performed double-blind by a single examiner. In addition, epidermal cells (not 
further characterised) were isolated, and mixed epidermal cell-(allogenic) lymphocyte reactions were 
performed with lymphocytes from three unrelated allogeneic donors. The Panel notes that no 
functional studies on the immune response against foreign antigens were provided. The Panel further 
notes that in the statistical analysis only within-group comparisons were reported, with no statistical 
comparison between the two groups. The Panel considers that no conclusions can be drawn from this 
study for the scientific substantiation of the claim. 
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One animal study on the effect of L. johnsonii on UV-induced immunosuppression was provided. The 
Panel considers that evidence provided in animal studies is not sufficient to predict the occurrence of 
an effect of Lactobacillus johnsonii La1 consumption on protection of the skin from UV-induced 
damage in humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of Lactobacillus johnsonii NCC 533 (La1) (CNCM I-1225) and protection of the skin 
from UV-induced damage. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, Lactobacillus johnsonii NCC 533 (La1) (CNCM I-1225), which is the 
subject of the health claims, is sufficiently characterised. 
Improving immune defence against pathogenic gastro-intestinal microorganisms (ID 896)  
 The claimed effect is “natural defence/immune system”. The target population is assumed to 
be the general population. Improving immune defence against pathogenic gastro-intestinal 
microorganisms is a beneficial physiological effect.  
 A cause and effect relationship has not been established between the consumption of 
Lactobacillus johnsonii NCC 533 (La1) (CNCM I-1225) and improving immune defence 
against pathogenic gastro-intestinal microorganisms.  
Protection of the skin from UV-induced damage (ID 900) 
 The claimed effect is “skin health”. The target population is assumed to be the general 
population. In the context of the clarifications provided by Member States, it is assumed that 
the claimed effect refers to protection of the skin from UV-induced damage. Protection of the 
skin from UV-induced damage is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
Lactobacillus johnsonii NCC 533 (La1) (CNCM I-1225) and protection of the skin from 
UV-induced damage.  
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1683, 
EFSA-Q-2008-1687). The scientific substantiation is based on the information provided by the 
Member States in the consolidated list of Article 13 health claims and references that EFSA has 
received from Member States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
6 OJ L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
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 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to Lactobacillus johnsonii NCC 533 (La1) (CNCM I-1225), 
including conditions of use from similar claims, as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
896 Lactobacillus johnsonii NCC 
533 (La1) (Pasteur culture 
collection CNCM I-1225) 
Natural defence/immune 
system 
Clarifications from MS: 
Improved host defences 
against infectious agents 
As recommended by 
PASSCLAIM, the functional 
capacity of the immune 
system has been assessed by: 
- measuring specific cell 
functions ex vivo 
- measuring in vivo 
responses to challenge, e.g. 
change in antibody in blood 
or response to antigens 
- determining the incidence 
and severity of infections  
- probiotic 
'-increases your natural 
defences; 
-actively supports your 
immune system; 
-strengthens your immune 
defences. 
Conditions of use 
- mind. 10E9 KBE/Tag, fermentierte Milch und sprühgetrocknet 
- at least 109 cfu/day Fermented milk and spray-dried  powder (supplement) 
ID Food or Food constituent Health Relationship Proposed wording 
900 Lactobacillus johnsonii NCC 
533 (La1) (Pasteur culture 
collection CNCM I-1225) 
Skin health 
Clarification provided 
Skin Health. Improved skin 
response to UV/sun exposure 
assessed by measuring: 
- the antigen-presenting 
capacity in a mixed 
epidermal cell lymphocyte 
reaction (MECLR) 
- the erythemal and 
pigmentation response   
'- probiotic -La1 helps to 
preserve skin health. + - helps 
to reinforce skin defences 
Conditions of use 
 at least 5x10[9] cfu/day, Powder 
 at least 5x109 cfu/day, Powder (supplement) 
Comments from Member States 
UK proposal identical to Dutch proposal 
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GLOSSARY AND ABBREVIATIONS 
CFU  Colony-forming unit  
CNCM  Collection Nationale de Cultures de Microorganismes  
IgA  Immunoglobulin A   
MED  Minimal erythemal dose  
NCBI  National Center for Biotechnology Information 
 
